StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) Mid-Quarter Review of FDA CLIA Waiver Approval Issued By Scimitar E

Share Name	Share Symbol	Market	Type
Chembio Diagnostics Inc	NASDAQ:CEMI	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.455	0.44	0.46				0	01:00:00

Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Chembio Diagnostics Charts.

BOSTON, Nov. 6 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of StatSure Diagnostic Systems, Inc. (OTC:SSUR) (BULLETIN BOARD: SSUR) , entitled, "FDA Approves CLIA Waiver for StatSure's Patented Barrel Technology for Rapid HIV Testing." This review is available at website: http://www.scimitarequity.com/. About StatSure StatSure Diagnostic Systems, Inc. (OTC:SSUR) (BULLETIN BOARD: SSUR) is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Inverness Medical Innovations, Inc. (AMEX:IMA), Chembio Diagnostics, Inc. (OTC:CEMI) (BULLETIN BOARD: CEMI) , and StatSure Diagnostic Systems, Inc. (OTC:SSUR) (BULLETIN BOARD: SSUR) announced in October of 2006 agreements that provide Inverness with exclusive worldwide marketing rights to Chembio's FDA- cleared, point of care, rapid test for the detection of antibodies to HIV. The test utilizes Inverness' proprietary lateral flow technology as well as StatSure's patented "barrel" technology designed to maximize ease of use and minimize exposure to infectious agents. Please visit website at http://www.statsure.com/ About Scimitar Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about SSUR.OB (NASDAQ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures. CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559.1080 fax: (617) 559.1083 e-mail: DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-559-1080, fax +1-617-559-1083, Web site: http://www.scimitarequity.com/ http://www.statsure.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CEMI Chembio Diagnostics Inc